Aptose secures $11.9M loan from Hanmi to fund tuspetinib AML study

Aptose Biosciences Inc.

Amended facility with Hanmi provides up to $11.9M in uncommitted advances through Dec 31, 2025; first advance expected soon.
Final $1.4M advance received under prior June 2025 facility, totaling $8.5M from that agreement.
Loan is a related-party transaction; Aptose relies on financial hardship exemption from formal valuation and minority approval.
Proceeds fund TUSCANY Phase 1/2 trial of tuspetinib + venetoclax + azacitidine in newly diagnosed AML patients.
Early data showed 9/10 patients responded; 100% CR/CRh at 80mg and 120mg cohorts across adverse mutations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.